NCT05467800进行中（未招募）2 期
A Phase 2 Study of Canakinumab in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 122]
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 14
- 试验地点
- 15
- 主要终点
- Number of participant with response based on IWG-MRT criteria
研究概览
简要总结
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles. Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks. The interim analysis will be performed when the number of enrolled patients reaches 10. If no responses OR 4 or more patients have unacceptable toxicity, the study will not proceed to the second stage. If the total number of patients reaches the maximum sample size of 26, the treatment is deemed acceptable if the number of responses in the efficacy endpoint are greater than 3, and the number of toxicities are less than 7.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The following are required for inclusion in the study:
- •Parts 1 and 2:
- •Participants must voluntarily sign informed consent form (ICF) and be willing and able to adhere to the study visit schedule and all protocol requirements.
- •Participants must be ≥ 18 years of age at the time of signing the ICF.
- •Participants must have a pathologically confirmed diagnosis of PMF as per the World Health Organization (WHO) diagnostic criteria46 or post-ET MF or post-PV MF according to IWG-MRT criteria.47
- •Participants must have at least one of the following:
- •Hemoglobin < 10 g/dL
- •Transfusion-dependency (at least 6 units of packed red blood cells (PRBC) in the 12 weeks prior to study enrollment, for a hemoglobin < 8.5 g/dL, in the absence of bleeding or treatment-induced anemia with the most recent transfusion having occurred in the 28 days prior to study enrollment)
- •Splenomegaly palpated ≥ 5 cm below the left costal margin (LCM) or spleen volume ≥ 450 cc
- •MFSAF v4.0 TSS ≥ 10
- •A bone marrow biopsy must be performed within the 30-day screening period; however, a bone marrow biopsy obtained within 90 days of signing ICF without intervening treatments and approved by the study chair may suffice.
- •Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
- •Life expectancy of at least 6 months.
- •Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments excluding alopecia.
- •Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within 28 days of starting the study drug. Men and women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence, tubal ligation, vasectomy) prior to Cycle 1 Day 1 and for 130 days after stopping study treatment. Vasectomy must be performed a minimum of 3 months before study start.
- •Must have adequate organ function as demonstrated by the following:
- •ALT/AST ≤ 3.0 x ULN, or ≤ 4 x ULN (unless if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
- •Direct bilirubin ≤ 1.5 x ULN or ≤ 2.0 x ULN (unless if upon judgment of the treating physician, it is believed to be due to EMH related to MF or documented Gilbert's syndrome);
- •Serum creatinine ≤ 2.0 mg/dL;
- •Platelet count ≥ 25 x 109/L (participant must not have had platelet transfusion in the 14 days prior to signing ICF);
- •ANC ≥ 1000/µL
- •Participant must be willing to receive red blood cell and/or platelet transfusions if indicated.
- •Bone marrow and peripheral blood blast count < 10%.
- •Part 1 Only:
- •At least two weeks must have elapsed between the last dose of any MF-directed drug treatments (including investigational therapies and excluding hydroxyurea) and study enrollment.
- •Not eligible for available, approved JAKi therapy due to a platelet count of < 50 x 109/L or previously treated and lack/loss of response per investigator discretion.
- •Part 2 Only:
- •Current treatment with a JAKi (inclusive of ruxolitinib, fedratinib, momelotinib, or pacritinib) for at least 16 weeks and on a stable or decreased dose for at least 12 weeks prior to study enrollment.
排除标准
- •Any of the following is a criterion for exclusion from the study:
- •Prior malignancy active within the previous ≤ 1 year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- •Any of the following cardiac abnormalities
- •Uncontrolled, symptomatic congestive heart failure as designated by the treating physician
- •Myocardial infarction ≤ 6 months prior to enrollment
- •Unstable angina pectoris designated by treating physician
- •Serious uncontrolled cardiac arrhythmia as designated by treating physician
- •Uncontrolled hypertension as designated by treating physician
- •Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with hepatitis B or Hepatitis C.
- •Active TB infection or documented, untreated latent TB infection (all participants should undergo TB risk evaluation prior to enrollment with TB screening performed as per local guidelines.)
- •Active, uncontrolled infection at the time of enrollment, except in cases of localized infections that are unlikely to lead to a systemic infection such as onychomycoses or dental caries.
- •a. Participants with a new fever (T>38.0o C) or respiratory symptoms are required to undergo laboratory screening for COVID-
- •Have undergone prior allo-HSCT for treatment of any hematological disorder or prior solid organ transplant
- •Any serious or uncontrolled psychiatric or medical disorder that, in the opinion of the investigator, may increase the risk associated with the study participation or study drug administration, impair the ability of the participants to receive protocol therapy, or interfere with the interpretation of study results.
- •Women who are pregnant or breastfeeding.
- •Participants undergoing concurrent treatment with agents targeting TNF-α or IL-1 within 28 days of study enrollment.
- •Participants who have received a live vaccination within 90 days before study drug administration (participants should not be treated with live-virus vaccine while undergoing therapy and 130 days after Canakinumab discontinuation).
- •Participants with a condition requiring systemic treatment with corticosteroids within 14 days of study drug administration (i.e. prednisone at doses of > 10 mg). Inhaled or topical steroids and adrenal/pituitary replacement doses ≤ 10mg daily of prednisone or equivalent are permitted.
研究组 & 干预措施
Canakinumab
Experimental
Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.
干预措施: Canakinumab (Drug)
结局指标
主要结局
Number of participant with response based on IWG-MRT criteria
时间窗: 24 weeks
Efficacy of Canakinumab as measured by number of participant with response based on the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria. A response is considered any one of the following: complete response, partial response, or clinical improvement (inclusive of anemia response, spleen response, or symptom response).
次要结局
- Change in Spleen Volume(24 weeks)
- Progression free survival (PFS)(24 weeks)
- Number of Adverse Events(24 weeks)
- Response using IWG-MRT(24 weeks)
- Number of participants with clinical improvement(24 weeks)
- Overall Survival (OS)(24 weeks)
研究者
John Mascarenhas
Professor
Icahn School of Medicine at Mount Sinai
研究点 (15)
Loading locations...
相似试验
终止
2 期
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisHepatomegalyMyelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhaseSplenomegalyPrimary MyelofibrosisNCT02421354M.D. Anderson Cancer Center8
已完成
2 期
Canakinumab for Pyoderma GangrenosumPyoderma GangrenosumNCT01302795University of Zurich5
招募中
2 期
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic SyndromeMyelodysplastic SyndromeChronic Myelomonocytic LeukemiaNCT04239157M.D. Anderson Cancer Center76
撤回
2 期
PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisMyelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisNCT04054245M.D. Anderson Cancer Center
终止
2 期
BIBW 2992 (Afatinib) and VinorelbineCarcinoma Breast Stage IVNCT01531764University of Magdeburg2